Most Mdm2 inhibitors have shown limited efficacy in Phase I trials, with significant thrombocytopenia emerging as a dose-limiting toxicity linked to prolonged Mdm2 inhibition (Table 1). This evidence concerns the gene MDM2 and Thrombocytopenia.